Fig. 7

Drug responses in anaplastic thyroid cancer (ATC) spheroid lines. (A) Workflow for evaluating cell viability in ATC spheroids using CellTiter-Glo 3D cell viability assay. (B) Representative images of ATC01 spheroids and monolayers in response to different drug treatments. (C) Drug-response analysis with dabrafenib, trametinib, and combination of both in ATC01 spheroids and monolayer cultured cells. (D) Representative images of 8505 C spheroids and monolayers in response to different drug treatments. (E) Drug-response analysis with dabrafenib, trametinib, and combination of both in 8505 C spheroids and monolayer cultured cells. (F) Representative images of C643 spheroids and monolayers in response to different drug treatments. (G) Drug-response analysis with dabrafenib, trametinib, and combination of both in C643 spheroids and monolayer cultured cells. Cell viability was measured by CellTiter-Glo assay after five days of drug treatment, and results were normalized to dimethyl sulfoxide-treated control cells. Each data point represents the mean ± SD of three technical duplicates. *P < 0.05 is the cell viability in the spheroid models compared to the cell viability in monolayer cultured cells, ns = nonsignificant. S = spheroids; M = monolayers; DAB = dabrafenib; TRA = trametinib; D + T = dabrafenib + trametinib, the combination ratio is 150:1, the dose-response curve of the combination group was plotted based on the doses of trametinib used in the treatment. The doses for trametinib in the combination group were 0.0085 µM, 0.017 µM, 0.033 µM, 0.067 µM, 0.133 µM. Based on the combination ratio (dabrafenib:trametinib = 150:1), the doses of dabrafenib in the combination group were 1.25 µM, 2.5 µM, 5 µM, 10 µM and 20 µM, respectively